

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Sepsis	Staphylocoagulase precursor (coa); von Willebrand factor binding protein (vWbp); ClfA	<p>Mouse studies suggest inhibiting the <i>Staphylococcus aureus</i> proteins coa, vWbp and ClfA could help treat sepsis. Coa and vWbp are secreted proteins that promote fibrin clotting, and ClfA promotes bacterial association with clots. In an <i>S. aureus</i> sepsis mouse model, combining antibodies against the three proteins, or combining a thrombin inhibitor with an anti-ClfA antibody, decreased agglutination and prolonged survival compared with any individual treatment. Next steps include developing a vaccine targeting the three proteins.</p> <p><b>SciBX 4(44); doi:10.1038/scibx.2011.1239</b>  <b>Published online Nov. 10, 2011</b></p>	Patent application filed; available for licensing	<p>McAdow, M. <i>et al. PLoS Pathog.</i>; published online Oct. 20, 2011; doi:10.1371/journal.ppat.1002307  <b>Contact:</b> Olaf Schneewind, The University of Chicago, Chicago, Ill.                      e-mail: <a href="mailto:oschnee@bsd.uchicago.edu">oschnee@bsd.uchicago.edu</a></p>